The global market for stem cell products was $3.8 billion in 2011. This market
is expected to reach nearly $4.3 billion in 2012 and $6.6 billion by 2016,
increasing at a compound annual growth rate (CAGR) of 11.7% from 2011 to 2016.
The American market for stem cell products was $1.3 billion in 2011. This
sector is expected to rise at a CAGR of 11.5% and reach nearly $2.3 billion by
2016.
The European market for stem cell products was $872 million in 2011 and is
expected to reach nearly $1.5 billion by 2016, a CAGR of 10.9%.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry
analyses to help readers quantify and qualify the market for prescription drug
products. Important trends are identified and sales forecasts by product
categories and major country markets are provided through 2016; these are
based on industry sources and considered assessment of the regulatory
environment, healthcare policies, demographics, and other factors that
directly affect the stem cell-related drug market. The wider economic
environment is also taken into account.
The report examines strategies employed by companies specializing in this
field to meet the challenges of a competitive and fast-growing market.
REASONS FOR DOING THE STUDY
Products based on stem cells do not yet form an established market, but unlike
some other potential applications of bioscience, stem cell technology has
already produced a number of significant products in important therapeutic
areas. The potential scope of the stem cell market is now becoming clear, and
it is appropriate to review the technology, see its practical applications so
far, evaluate the participating companies and look to its future.
SCOPE OF REPORT
This report discusses the implications of stem cell research and commercial
trends in the context of the current size and growth of the pharmaceutical
market, both in global terms and analyzed by the most important national
markets. The important technologies supporting stem cells are reviewed, and
the nature and structure of the stem cell industry is discussed with profiles
of the leading companies, including recent M&A activity. Five-year sales
forecasts are provided for the national markets and the major therapeutic
categories of products involved.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are
projected at 2012-dollar value without attempting to predict the effect of
inflation/deflation. Therapeutic categories quantified and forecast include
cancer, CNS diseases, infections and cardiovascular. Major country markets in
three regions - Americas, Europe and Asia - are analyzed and forecast, with a
summary for the rest of the world.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. Primary research includes interviews with leading individuals in stem
cell companies and industry associations. Primary sources of published data
include company annual reports, SEC filings, and government and industry
publications. Secondary sources consist of literature searches, industry
journals and other commercial publications. Data for market estimates and
forecasts are pooled from a range of sources, critically assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of
individuals involved in the pharmaceutical marketplace, including company
senior management executives seeking to base their strategic decisions on the
best available information on market forces and trends. However it is also
aimed at managers and executives in marketing, research, planning and sales
departments who need readable, comprehensive and up-to-date background on the
marketplace in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government agencies and regulatory bodies, and surveys of physicians and
pharmacists. Company annual reports and SEC filings, journal articles, and
data from healthcare institutions were also reviewed.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets
for 20 years. He is the author of previous reports on the stem cell
marketplace as well as analyses of major therapeutic categories and the
pharmaceutical regulatory environment.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
MARKET ANALYSES AND FORECASTS
METHODOLOGY
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter- 2: SUMMARY
DEFINITIONS
APPLICATIONS
RESEARCH AND COMMERCIALIZATION
MARKET
Chapter- 3: OVERVIEW
CELLS
STEM CELLS
Chapter- 4: STEM CELL RESEARCH
HISTORY
CELL-BASED THERAPEUTICS
REGULATION OF STEM CELL RESEARCH
PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION
Chapter- 5: STEM CELL APPLICATIONS
REGENERATIVE MEDICINE
CURRENT APPLICATIONS OF STEM CELL THERAPY
Chapter- 6: STEM CELL PATENTS
GENERAL BACKGROUND ON PATENTS
STEM CELL PATENTS
INDIVIDUAL COUNTRY POLICIES
Chapter- 7: STEM CELL MARKETS
MARKETS FOR STEM CELLS
MARKET OPPORTUNITIES BY THERAPEUTIC CLASS
REGIONAL AND NATIONAL MARKET ANALYSIS
Chapter- 8: COMPANY PROFILES
3DM
AASTROM BIOSCIENCES, INC.
ADVANCED CELL TECHNOLOGY, INC.
ALDAGEN, INC.
ANGIOBLAST SYSTEMS
ARTERIOCYTE
ATHERSYS INC.
BEIKE BIOTECHNOLOGY CO., LTD.
BioE
BIOHEART, INC.
BIOTIME, INC.
BRAINSTORM CELL THERAPEUTICS INC.
CAPRICOR, INC.
CARDIO3 BIOSCIENCES
CELLARTIS AB
CELLERANT THERAPEUTICS, INC.
CELLERIX SA
CELLULAR DYNAMICS INTERNATIONAL
CYTORI THERAPEUTICS, INC.
EPISTEM LTD.
FORTICELL BIOSCIENCE, INC.
GAMIDA CELL, LTD.
GLOBALSTEM
HYBRID ORGAN GMBH
INTELLICELL BIOSCIENCES, INC.
INTERNATIONAL STEM CELL CORPORATION
JUVENTAS THERAPEUTICS, INC.
MEDISTEM INC.
MESOBLAST LTD.
NEOSTEM, INC.
NEURALSTEM
NEUROGENERATION
OSIRIS THERAPEUTICS, INC.
PHARMASTEM THERAPEUTICS, INC.
PLUREON CORPORATION
PRIMEGEN BIOTECH, LLC
RENEURON GROUP
RHINOCYTE INC.
STEM CELLS INC.
STEMCELL TECHNOLOGIES SARL
STEM CELL THERAPEUTICS CORP.
STEMEDICA CELL TECHNOLOGIES, INC.
STEMINA BIOMARKER DISCOVERY INC.
STEMPEUTICS RESEARCH PVT. LTD.
TIGENIX NV
TRISTEM CORPORATION
VERASTEM, INC.
VERISTEM TECHNOLOGIES
VIACYTE
VITRO DIAGNOSTICS, INC.
WICELL RESEARCH INSTITUTE
XPAND BIOTECHNOLOGY BV
Chapter- 9: APPENDIX 1: GLOSSARY
Chapter- 10: APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS
Table 59 : SIGNIFICANT STEM CELL RESEARCH PATENTS
List of Tables
Summary Table : GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016
Table 1 : COUNTRIES ENGAGED IN THE ISCBI PROGRAM
Table 2 : IPS-RELATED PATENTS (YAMANAKA, 2011)
Table 3 : CLASSIFICATION OF STEM CELL PATENTS
Table 4 : HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
Table 5 : EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
